Breaking News

SGS Adds Stability Testing Services in UK

March 11, 2013

Expands analytical testing for biologics

SGS Life Science Services is developing integrated formulation and stability testing services in the UK, expanding its current capability for characterization-based analytical testing for biologics. The new services will be offered from a dedicated suite in its M-Scan facility in Wokingham, UK and is scheduled to be fully operational by 4Q13.
 
The 1,100 sq.-ft. suite will include a temperature and access controlled room for the stability units and a large separate instrumentation and wet lab. These new services extend SGS’s formulation and stability services currently provided in Lincolnshire, IL, and stability testing services from its Center of Excellence in Berlin, Germany.
 
“Customers require preparation and testing of their samples at one site. Sample shipment involved in multisite testing is not ideal because of the potential effects that shipping may have on sample integrity,” said Andrew Reason, group manager, SGS M-Scan Europe. “These studies are also an iterative process whereby data is fed back to the formulation scientists prior to generation of further samples for testing.”
 
Anne Hays, executive vice president, SGS Life Science Services, said, “There is an increasing trend for biologics manufacturers to outsource testing of their products and SGS strives to provide new services in response to the market’s needs in a timely manner.”
  • Analytical Testing Outsourcing Trends Update

    Analytical Testing Outsourcing Trends Update

    January 26, 2017
    Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research